BMCS New approaches to the treatment of Parkinson’s
Event
New approaches to the treatment of Parkinson’s
Date
Wednesday, 12th November, 2025
Place
Burlington House, Piccadilly, London, W1J 0BA
Downloads and Links
X hashtag – #BMCSPARKINSONS2025
Synopsis
Join the Royal Society of Chemistry Biological Medicinal Chemistry Sector and Parkinson’s UK to hear about new approaches to the treatment of Parkinson’s Disease.
In the dynamic field of drug discovery, the search for new treatments for Parkinson’s disease has never been more critical. It is estimated 10 million people worldwide are living with Parkinson’s – a chronic, progressive neurodegenerative condition resulting from the loss of the dopamine-containing cells of the substantia nigra. Motor and non-motor symptoms of the condition are wide ranging and current treatments only help to manage a small subset of the symptoms and do not modify the disease progression. But there is a wealth of research to find new and better therapeutics for Parkinson’s.
This meeting, specifically designed for professionals dedicated to developing new therapeutics for Parkinson’s disease, will highlight current research offering symptomatic relief and disease modifying approaches.
Want to become an RSC member?
To join the RSC in order to qualify for discounted registration fees at all RSC events, please follow this RSC link
Call for Abstracts
Abstract submission is now open, please click here to access the abstract template. All submissions should be emailed to events@hg3.co.uk
Deadline for submissions – Midnight (BST) 5th September, 2025.
Student Bursaries
The RSC-BMCS are offering a small number of bursaries to attend the meeting in person. Applications are open to PhD and post-doctoral applicants studying at academic institutions or non-profit institutions. Preference will be given to members of the RSC-BMCS. Bursary applications are also invited from RSC or EFMC members who are of working age, but currently unemployed and from those who may have difficulty in funding their attendance. The bursary application deadline is Friday 29th August 2025.
Please click here to complete the application form.
Please send all completed application forms to events@hg3.co.uk
Registration
Registration is now open, please click here to register!
In person registration fees
RSC Member £180
Non Member £210
RSC Student Member £100
Student Non-Member £130
Online attendance registration fees
RSC Member £70
Non Member £90
RSC Student Member £30
Student Non-Member £50
Sponsorship/Exhibition Opportunities
Bookings to sponsor or exhibit at the meeting are now open, click here to register.
Exhibition Package includes (£750):
– One stand personnel with access to technical sessions
– A six-foot trestle table and chair(s)
– Electrical and Wi-Fi access
– Your logo and full promotional page in the pdf of the delegate handbook
– Your logo in the rolling slides, shown during the breaks
– Any additional stand personnel will have to be booked as delegates
Sponsorship:
We are also seeking sponsorship from organisations supporting the low registration fees offered to students.
All sponsor logo’s will be displayed on the holding slides, pdf of the delegate handbook and included in the communications to delegates. Your company logo and website link will be displayed on the conference website.
Confirmed Speakers:
David Harrison, Nodthera
From serendipity to study in patients: The development of NLRP3 inflammasome inhibitor NT-0796 for the treatment of Parkinson’s disease
Gilles Ouvry, NRG Therapeutics
Orally available, brain penetrant mPTP inhibitors for the treatment of Parkinson’s
Jonathan Powell, Domainex
Talk title TBC
Anne Valade, UCB
Discovery of glovadalen (UCB0022), an oral, brain penetrant positive allosteric modulator of the dopamine D1 receptor (D1 PAM) currently in Phase 2 clinical trial
Organising Committee
Nadia Ahmad , Charles River
Jan Kulagowski
Chris Swain, Cambridge MedChem Consulting
Iwona Ziomkiewicz, Parkinson’s UK
Secretariat Contact and Further Information
Hg3 Conferences Ltd
+44 (0)1423 529333
E-mail
